By Clinical Informatics News Staff

December 14, 2018 | Eli Lilly and Evidation Health have expanded their collaboration with a multi-year agreement to provide Lilly with global access to Evidation’s Andromeda data platform.

Evidation Health is a health and measurement company that helps life sciences and health care companies understand how everyday behavior and health interact. As a result of this announcement, Lilly scientists and researchers across therapeutic portfolios will have access to Evidation’s data platform with the goal of uncovering new ways to measure and understand a patient’s health by accessing consented data derived from smartphones, connected sensors, wearables, and even his or her own voice. The terms of the agreement are undisclosed.

“Digital health advancements, including mobile devices and wearables, have the potential to improve and personalize health outcomes,” said Divakar Ramakrishnan, Lilly’s Chief Digital Officer, in a statement. “By leveraging Evidation’s Andromeda platform, Lilly’s scientists are gaining a deeper understanding of the physiological, environmental, and contextual indicators that can help shape future advancements in medicine and medicine delivery.”

With Andromeda, Lilly scientists now have instant access to a private, collaborative, and secure analytical environment where they can use powerful, Evidation-built algorithms to process raw data for use in clinical studies or to create their own predictive models. The models turn complex, patient-generated behavior data into novel, quantifiable, and clinically meaningful insights that can transform how diseases are identified, treated, and monitored.

As one example among multiple therapeutic areas, Evidation’s data platform is being used by Lilly to analyze data from continuous glucose monitors, insulin pumps, and real world information to improve the experience of people with diabetes and support the company’s significant efforts to build a connected ecosystem that includes an automated insulin delivery device and connected insulin pen.

“Our initial collaborations with Lilly demonstrated that digital biomarkers can play a significant role in understanding individuals and disease, and we are excited to expand our collaboration,” said Christine Lemke, co-founder and president of Evidation in the same statement. “The data platform product embodies an industry-wide change to the way we measure health, which makes it more proactive, objective, and ultimately meaningful to individuals.”